Emphasizing the importance of promoting policies that improve patient outcomes and lead to healthier, safer communities, the National Association of Chain Drug Stores submitted a statement to the U.S. House Committee on Energy and Commerce Subcommittee on Health in lead-up to Tuesday’s hearing titled, “Examining Public Health Legislation to Help Patients and Local Communities.”
Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.
Four House representatives on Thursday reintroduced legislation designed to help prevent prescription drug abuse and diversion and ensure patient access to necessary medications.
Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.
NeuroMetrix is making a splash at this year's International Consumer Electronics Show with its launch of Quell, an OTC chronic pain relieving device.
Use of cigarettes, alcohol and abuse of prescription pain relievers among teens has declined since 2013, while marijuana use rates were stable, according to the 2014 Monitoring the Future survey, released Tuesday.
From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period.
A study being published in Annals of Internal Medicine suggests that people with atrial fibrillation who take NSAIDs may be at risk for serious bleeding or thromboembolisms.
Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.